5e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human ROR1 Protein, His Tag (Cat. No. RO1-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Anti-Human ROR1 mAb captured on CM5 chip via anti-mouse antibodies surface can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His, Avitag (Cat. No. RO1-H82E6) with an affinity constant of 5.81 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| ROR1R-CAR | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center, Cll Global Research Foundation Alliance | Leukemia | Details | |
| NBE-002 | NBE-002 | Phase 2 Clinical | Nbe-Therapeutics Ag | Triple Negative Breast Neoplasms | Details |
| Cirmtuzumab | UC-961 | Phase 2 Clinical | University Of California | Ovarian Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| NVG-111 | NVG-111 | Phase 2 Clinical | NovalGen Ltd | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| VLS-101 | VLS-101; MK-2140 | Phase 2 Clinical | Velosbio, Merck Sharp & Dohme Corp | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung | Details |
| GNC-035 quadr-specific antibody（baili） | GNC-035 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
